{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T08:09:49Z","timestamp":1794038989665,"version":"4.8.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40265-020-01417-6","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T07:02:45Z","timestamp":1602140565000},"page":"1745-1750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clascoterone: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"issue":"2","key":"1417_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40257-019-00493-z","volume":"21","author":"DH Marks","year":"2020","unstructured":"Marks DH, Prasad S, De Souza B, et al. Topical antiandrogen therapies for androgenetic alopecia and acne vulgaris. Am J Clin Dermatol. 2020;21(2):245\u201354.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1417_CR2","first-page":"30","volume":"19","author":"JQ Del Rosso","year":"2020","unstructured":"Del Rosso JQ, Kircik LH, Stein Gold L, et al. Androgens, androgen receptors, and the skin: from the laboratory to the clinic with emphasis on clinical and therapeutic implications. J Drugs Dermatol. 2020;19(3):30\u20135.","journal-title":"J Drugs Dermatol"},{"key":"1417_CR3","unstructured":"Cassiopea. Winlevi\u00ae (clascoterone) cream: US prescribing information. 2020. https:\/\/www.cassiopea.com\/wp-content\/uploads\/2020\/08\/WINLEVI-clascoterone-cream-prescribing-info-08-2020.pdf. Accessed 10 Sept 2020."},{"issue":"5","key":"1417_CR4","first-page":"412","volume":"18","author":"C Rosette","year":"2019","unstructured":"Rosette C, Agan FJ, Mazzetti A, et al. Cortexolone 17alpha-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1417_CR5","first-page":"197","volume":"18","author":"C Rosette","year":"2019","unstructured":"Rosette C, Rosette N, Mazzetti A, et al. Cortexolone 17alpha-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol. 2019;18(2):197\u2013201.","journal-title":"J Drugs Dermatol"},{"key":"1417_CR6","unstructured":"US FDA. NDA (213433) approval: Winlevi (clascoterone) cream. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2020\/213433Orig1s000ltr.pdf. Accessed 8 Sept 2020."},{"key":"1417_CR7","unstructured":"Cosmo Pharmaceuticals. Cosmo announces FDA acceptance of investigational new drug application for CB-03-01 [media release]. 12 Mar 2012. https:\/\/www.cosmopharma.com\/."},{"key":"1417_CR8","unstructured":"Cosmo Pharmaceuticals. Cosmo licenses its anti-androgen for certain topical applications [media release]. 16 Apr 2012. https:\/\/www.cosmopharma.com\/."},{"issue":"12","key":"1417_CR9","first-page":"881","volume":"54","author":"G Celasco","year":"2004","unstructured":"Celasco G, Moro L, Bozzella R, et al. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881\u20136.","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"1417_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamadermatol.2020.0464","volume":"156","author":"JS Barbieri","year":"2020","unstructured":"Barbieri JS. A new class of topical acne treatment addressing the hormonal pathogenesis of acne. JAMA Dermatol. 2020;156(6):619\u201320.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1417_CR11","first-page":"563","volume":"18","author":"A Mazzetti","year":"2019","unstructured":"Mazzetti A, Moro L, Gerloni M, et al. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1417_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","volume":"156","author":"A Hebert","year":"2020","unstructured":"Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621\u201330.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1417_CR13","first-page":"570","volume":"18","author":"A Mazzetti","year":"2019","unstructured":"Mazzetti A, Moro L, Gerloni M, et al. A phase 2b, randomized, double-blind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial acne. J Drugs Dermatol. 2019;18(6):570.","journal-title":"J Drugs Dermatol."},{"issue":"1","key":"1417_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2133.2011.10332.x","volume":"165","author":"V Trifu","year":"2011","unstructured":"Trifu V, Tiplica GS, Naumescu E, et al. Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. Br J Dermatol. 2011;165(1):177\u201383.","journal-title":"Br J Dermatol."},{"key":"1417_CR15","unstructured":"Cassiopea. Cassiopea announces very positive phase II twelve months results for Breezula\u00ae (clascoterone) in treating androgenetic alopecia [media release]. 16 Apr 2019. https:\/\/www.cassiopea.com\/."},{"issue":"2","key":"1417_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jaad.2020.04.087","volume":"83","author":"L Eichenfield","year":"2020","unstructured":"Eichenfield L, Hebert A, Gold LS, et al. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. J Am Acad Dermatol. 2020;83(2):477\u201385.","journal-title":"J Am Acad Dermatol"},{"key":"1417_CR17","unstructured":"Cassiopea. Cassiopea announces first patient to be enrolled in phase II trial for the treatment of androgenetic alopecia in females with clascoterone solution [media release]. 13 Nov 2019. https:\/\/www.cassiopea.com\/."},{"key":"1417_CR18","unstructured":"Cassiopea. Cassiopea announces results for first half of 2020 [media release]. 29 Jul 2020. https:\/\/www.cassiopea.com\/."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01417-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01417-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01417-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T08:23:37Z","timestamp":1633681417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01417-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":18,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1417"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01417-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"8 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate and consent for publication, Availability of data and material, Code availability"}}]}}